NLINKN1 Chip+PRIME.StudySYNCRStentrode+$75M.SeriesDPRECNLayer 7+FDA.BrkthruPARAMArgo+$20M.SeriesBBLKRKNeuroport+200.ImplantsEMTIVMN8+$45M.SeriesBKRNLFlux+Non-invasiveNRBLEHalo+Consumer.BCINEURONeuroPace+RNS.SystemCOGNICognixion+ALS.TrialFUND.YTD2026$2.8B.SectorTRIALSActive50+.ClinTrialsIMPLNTSHumans~100.Intracrtnl
Terminal/Device DB/DOT Microstimulator
minimally-invasivenoneinvestigational

DOT Microstimulator

Implant Type
minimally-invasive
Electrodes
1
Channels
1
FDA Status
none
Clinical Stage
Intraoperative human validation completed; clinical trials expected H1 2026
Status
investigational
About

Motif Neurotech's DOT is a blueberry-sized (9mm wide), leadless, batteryless implantable brain stimulator placed in the skull during a 20-minute outpatient procedure without ever exposing or contacting the brain. Receives data and power wirelessly from an external cap-like device via patented magnetoelectric power transfer technology developed at Rice University. Provides cell-type specific stimulation and electrical recording to regulate brain-wide circuits. Multiple DOTs can be networked to span the cortical surface for bilateral or multi-region stimulation. First product targets treatment-resistant depression. Intraoperative human studies demonstrated safe and effective stimulation, with 30+ day large animal studies completed.

Target Conditions
treatment-resistant depressionbipolar disorderAlzheimer's diseasesubstance use disorder
Milestones
2022-01Motif Neurotech founded via Rice Biotech Launch Pad
2024-06$18.75M Series A closed
2025-01UK ARIA multimillion-dollar award for therapeutic BCI development
2025-06Intraoperative human validation published on medRxiv
2025-12Patient registry launched for treatment-resistant depression
2026-01Clinical trials expected to begin H1 2026
FDA Regulatory Pathway
No FDA Regulatory Status

This device does not have a current FDA designation. It may be a research tool, preclinical device, or consumer product not subject to FDA medical device regulation.

FDA Device Regulatory Guidance ↗